If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? (Q81212513)
Jump to navigation
Jump to search
scientific article published on 01 April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? |
scientific article published on 01 April 2008 |
Statements
If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? (English)